Payment overview · 2025
General Payments
$410.58
22 reported records · 13 companies
Healthcare provider profile · identity verified
Brian Keith Bracy, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · FAYETTEVILLE, AR · NPI 1770798878
Verified facts
What the public records show
CMS Open Payments records show Brian Keith Bracy, M.D. received $410.58 in general payments during 2025 across 22 reported records.
Novo Nordisk Inc accounted for 20.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro, Ozempic, Voquezna.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported HUMIRA as an associated drug or biological on 1828 records involving 689 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Humira by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Ubrelvy by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Eliquis by this doctor in 2024.
Phathom Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VOQUEZNA as an associated drug or biological on 90302 records involving 33442 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Voquezna by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $82.42 | 20.1% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $42.13 | 10.3% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $38.80 | 9.4% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $38.16 | 9.3% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $35.51 | 8.7% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $34.51 | 8.4% | 2 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $31.31 | 7.6% | 2 | 2025 |
| Metacel Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $26.34 | 6.4% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $22.38 | 5.5% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $19.10 | 4.7% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $17.14 | 4.2% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $16.28 | 4.0% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $6.50 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $410.58 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $61.76 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $42.13 | 2 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $38.80 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $38.16 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $35.51 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $34.51 | 2 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $31.31 | 2 | 2025 |
Source payment records
|
|||||
| OZOBAX Normalized: ozobax |
Drug | Metacel Pharmaceuticals LLC | $26.34 | 1 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $22.38 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $20.66 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $20.66 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $20.42 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $19.10 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $17.14 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.90 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $16.28 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $15.09 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $6.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 66 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 66 | exact normalized | Medicare Part D |
| VOQUEZNA voquezna |
2025 | Voquezna | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | HUMIRA open payments reported associated product |
CMS Open Payments — General Payments 1828 supporting records · 689 recipient NPIs · example record 1201353784 |
Humira · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
66 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
66 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Phathom Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | VOQUEZNA open payments reported associated product |
CMS Open Payments — General Payments 90302 supporting records · 33442 recipient NPIs · example record 1219216983 |
Voquezna · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 304 | 42 |
| Atorvastatin Calcium | Atorvastatin Calcium | 262 | 62 |
| Levothyroxine Sodium | Levothyroxine Sodium | 156 | 38 |
| Omeprazole | Omeprazole | 153 | 43 |
| Tramadol Hcl | Tramadol Hcl | 146 | 29 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 143 | 24 |
| Metformin Hcl | Metformin Hcl | 135 | 36 |
| Propranolol Hcl | Propranolol Hcl | 121 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 109 | 31 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 99 | 30 |
| Ondansetron Odt | Ondansetron | 94 | 23 |
| Trazodone Hcl | Trazodone Hcl | 91 | 19 |
| Meloxicam | Meloxicam | 89 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 89 | 11 |
| Clonazepam | Clonazepam | 88 | 12 |
| Lisinopril | Lisinopril | 83 | 25 |
| Oxycodone Hcl | Oxycodone Hcl | 82 | suppressed |
| Baclofen | Baclofen | 81 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 75 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 75 | 20 |
| Bupropion Xl | Bupropion Hcl | 73 | suppressed |
| Valsartan | Valsartan | 73 | 17 |
| Alprazolam | Alprazolam | 72 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 71 | 11 |
| Ibuprofen | Ibuprofen | 71 | 22 |
| Tizanidine Hcl | Tizanidine Hcl | 70 | 18 |
| Pantoprazole Sodium | Pantoprazole Sodium | 68 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 68 | suppressed |
| Mounjaro | Tirzepatide | 66 | suppressed |
| Ozempic | Semaglutide | 66 | 15 |
| Amlodipine Besylate | Amlodipine Besylate | 65 | 20 |
| Carvedilol | Carvedilol | 57 | 14 |
| Naproxen | Naproxen | 57 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 53 | 42 |
| Losartan Potassium | Losartan Potassium | 53 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 50 | suppressed |
| Furosemide | Furosemide | 50 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 50 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 50 | 13 |
| Pregabalin | Pregabalin | 49 | suppressed |
| Diazepam | Diazepam | 48 | suppressed |
| Glipizide | Glipizide | 46 | suppressed |
| Lorazepam | Lorazepam | 46 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 46 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 45 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 43 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 41 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 41 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 40 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 39 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 39 | 15 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 38 | suppressed |
| Prednisone | Prednisone | 38 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 37 | suppressed |
| Methylprednisolone | Methylprednisolone | 36 | 24 |
| Morphine Sulfate Er | Morphine Sulfate | 36 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 35 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 32 | suppressed |
| Atenolol | Atenolol | 30 | suppressed |
| Ezetimibe | Ezetimibe | 29 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Eliquis | Apixaban | 28 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 27 | suppressed |
| Levofloxacin | Levofloxacin | 25 | 21 |
| Methocarbamol | Methocarbamol | 25 | suppressed |
| Potassium Chloride | Potassium Chloride | 24 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 20 | suppressed |
| Spironolactone | Spironolactone | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 16 |
| Memantine Hcl | Memantine Hcl | 19 | suppressed |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 17 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 16 | suppressed |
| Ibu | Ibuprofen | 16 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 16 | suppressed |
| Etodolac | Etodolac | 15 | suppressed |
| Ubrelvy | Ubrogepant | 15 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Voquezna | Vonoprazan Fumarate | 14 | suppressed |
| Azithromycin | Azithromycin | 13 | 11 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 13 | suppressed |
| Nadolol | Nadolol | 13 | suppressed |
| Nexletol | Bempedoic Acid | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | suppressed |
| Nucynta Er | Tapentadol Hcl | 13 | suppressed |
| Simvastatin | Simvastatin | 13 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 12 | suppressed |
| Levetiracetam Er | Levetiracetam | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 11 | suppressed |
| Humira | Adalimumab | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $410.58 · 22 records | Novo Nordisk Inc | BOTOX, BREZTRI, CONTRAVE, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, FREESTYLE LIBRE, MOUNJARO, NURTEC ODT, OZOBAX, Ozempic, Rybelsus, Symbravo, VOQUEZNA, Wegovy, XYOSTED, ZAVZPRET, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error